» Articles » PMID: 38791277

Functional Characterization of a Spectrum of Genetic Variants in a Family with Succinic Semialdehyde Dehydrogenase Deficiency

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 May 25
PMID 38791277
Authors
Affiliations
Soon will be listed here.
Abstract

Succinic semialdehyde dehydrogenase (SSADH) is a mitochondrial enzyme involved in the catabolism of the neurotransmitter γ-amino butyric acid. Pathogenic variants in the gene encoding this enzyme cause SSADH deficiency, a developmental disease that manifests as hypotonia, autism, and epilepsy. SSADH deficiency patients usually have family-specific gene variants. Here, we describe a family exhibiting four different SSADH variants: Val90Ala, Cys93Phe, and His180Tyr/Asn255Asp (a double variant). We provide a structural and functional characterization of these variants and show that Cys93Phe and Asn255Asp are pathogenic variants that affect the stability of the SSADH protein. Due to the impairment of the cofactor NAD binding, these variants show a highly reduced enzyme activity. However, Val90Ala and His180Tyr exhibit normal activity and expression. The His180Tyr/Asn255Asp variant exhibits a highly reduced activity as a recombinant species, is inactive, and shows a very low expression in eukaryotic cells. A treatment with substances that support protein folding by either increasing chaperone protein expression or by chemical means did not increase the expression of the pathogenic variants of the SSADH deficiency patient. However, stabilization of the folding of pathogenic SSADH variants by other substances may provide a treatment option for this disease.

Citing Articles

A crucial active site network of titratable residues guides catalysis and NAD binding in human succinic semialdehyde dehydrogenase.

Cesaro S, Orlando M, Bettin I, Longo C, Spagnoli G, Polverino de Laureto P Protein Sci. 2024; 34(1):e70024.

PMID: 39731543 PMC: 11681614. DOI: 10.1002/pro.70024.

References
1.
Kirkegaard T, Gray J, Priestman D, Wallom K, Atkins J, Olsen O . Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med. 2016; 8(355):355ra118. PMC: 6821533. DOI: 10.1126/scitranslmed.aad9823. View

2.
Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N . Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds. Proc Natl Acad Sci U S A. 2010; 107(12):5569-74. PMC: 2851769. DOI: 10.1073/pnas.0914960107. View

3.
Didiasova M, Banning A, Brennenstuhl H, Jung-Klawitter S, Cinquemani C, Opladen T . Succinic Semialdehyde Dehydrogenase Deficiency: An Update. Cells. 2020; 9(2). PMC: 7072817. DOI: 10.3390/cells9020477. View

4.
Parenti G, Andria G, Valenzano K . Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. Mol Ther. 2015; 23(7):1138-1148. PMC: 4817787. DOI: 10.1038/mt.2015.62. View

5.
Kim Y, Lee S, Kwon O, Park S, Lee S, Park B . Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009; 28(7):959-68. PMC: 2670868. DOI: 10.1038/emboj.2009.40. View